The psychopharmacology algorithm project at the Harvard South Shore program: An algorithm for acute mania

Harvard Review of Psychiatry

Volumn 22, Issue 5, 2014, Pages 274-294

  Mohammad, Othman ^a   Osser, David N ^b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Algorithm; Bipolar disorder; Management; Mania; Psychopharmacology

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ASENAPINE; CARBAMAZEPINE; CLOZAPINE; HALOPERIDOL; LITHIUM; OLANZAPINE; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZIPRASIDONE; NEUROLEPTIC AGENT;

ALGORITHM; BIPOLAR DEPRESSION; BIPOLAR DISORDER; DEPRESSION; DSM-5; ELECTROCONVULSIVE THERAPY; HUMAN; MANIA; MIXED MANIA AND DEPRESSION; MONOTHERAPY; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RELAPSE; REVIEW; CLINICAL PROTOCOL; STANDARDS;

ALGORITHMS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CLINICAL PROTOCOLS; HUMANS; PSYCHOPHARMACOLOGY;

EID: 84925845817     PISSN: 10673229     EISSN: 14657309     Source Type: Journal    
DOI: 10.1097/HRP.0000000000000018     Document Type: Review

References (190)

1. Levy B, Weiss RD. Neurocognitive impairment and psychosis in bipolar I disorder during early remission from an acute episode of mood disturbance. J Clin Psychiatry 2010;71:201-6.
2. Ansari A, Osser DN. The psychopharmacology algorithm projectat the Harvard South Shore Program: anupdate onbipolar depression. Harv Rev Psychiatry 2010;18:36-55.
3. Osser DN, Jalali-Roudsari M, Manschreck T. The Psychopharmacology Algorithm Project at the Harvard South Shore Program: an update on schizophrenia. Harv Rev Psychiatry 2013;21:18-40.
4. Bajor LA, Ticlea AN, Osser DN. The Psychopharmacology Algorithm Project at the Harvard South Shore Program: an update on posttraumatic stress disorder. Harv Rev Psychiatry 2011;19:240-58.
5. Hamoda HM, Osser DN. The Psychopharmacology Algorithm Project at the Harvard South Shore Program: an update on psychotic depression. Harv Rev Psychiatry 2008;16:235-47.
6. Osser DN, Dunlop LR. The Psychopharmacology Algorithm Project at the Harvard South Shore Program: an update on generalized social anxiety disorder. Psychopharm Rev 2010;45:91-8.
7. National Collaborating Centre for Mental Health; National Institute for Health and Clinical Excellence. Bipolar disorder: the management of bipolar disorder in adults, children, and adolescents in primary and secondary care. London: NICE, 2006.
8. Goodwin FK, Jamison KR. Manic-depressive illness: bipolar disorders and recurrent depression. 2nd ed. New York: Oxford University Press, 2007.
9. Rosa AR, Cruz N, Franco C, et al. Why do clinicians maintain antidepressants in some patients with acute mania? Hints from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM), a large naturalistic study. J Clin Psychiatry 2010;71:1000-6.
10. McElroy SL, Keck PE Jr, Strakowski SM. Mania, psychosis, and antipsychotics. J Clin Psychiatry 1996;57 suppl 3:14-26; discussion 47-9.
11. Swann AC, Daniel DG, Kochan LD, Wozniak PJ, Calabrese JR. Psychosis in mania: specificity of its role in severity and treatment response. J Clin Psychiatry 2004;65:825-9.
12. Carlson GA, Goodwin FK. The stages of mania. A longitudinal analysis of the manic episode. Arch Gen Psychiatry 1973;28:221-8.
13. Yildiz A, Vieta E, Tohen M, Baldessarini RJ. Factors modifying drug and placebo responses in randomized trials for bipolar mania. Int J Neuropsychopharmacol 2011;14:863-75.
14. Schatzberg AF, Cole JO, DeBattista C. Manual of clinical psychopharmacology. 7th ed. Washington, DC: American Psychiatric Press, 2010.
15. Janicak PG, Marder SR, Pavuluri MN. Principles and practice of psychopharmacotherapy. 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2011.
16. American Psychiatric Association. American Psychiatric Association practice guidelines for the treatment of psychiatric disorders. Arlington, VA: American Psychiatric Publishing, 2006.
17. Battaglia J, Moss S, Rush J, et al. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med 1997;15:335-40.
18. Garza-Trevino ES, Hollister LE, Overall JE, Alexander WF. Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. Am J Psychiatry 1989;146:1598-601.
19. Andrezina R, Josiassen RC, Marcus RN, et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophreniaor schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology (Berl) 2006;188:281-92.
20. Satterthwaite TD, Wolf DH, Rosenheck RA, Gur RE, Caroff SN. A meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation. J Clin Psychiatry 2008;69:1869-79.
21. Zeller SL, Rhoades RW. Systematic reviews of assessment measures and pharmacologic treatments for agitation. Clin Ther 2010;32:403-25.
22. Mantovani C, Labate CM, Sponholz A Jr, et al. Are low doses of antipsychotics effective in the management of psychomotor agitation? A randomized, rated-blind trial of 4 intramuscular interventions. J Clin Psychopharmacol 2013;33:306-12.
23. Ahmed U, Jones H, Adams CE. Chlorpromazine for psychosis induced aggression or agitation. Cochrane Database Syst Rev 2010; (4): CD007445.
24. Karmacharya R, England ML, Ongur D. Delirious mania: clinical features and treatment response. J Affect Disord 2008;109:312-6.
25. Provencher MD, Guimond AJ, Hawke LD. Comorbid anxiety in bipolar spectrum disorders: a neglected research and treatment issue? J Affect Disord 2012;137:161-4.
26. Trixler M, Gati A, Fekete S, Tenyi T. Use of antipsychotics in the management of schizophrenia during pregnancy. Drugs 2005;65:1193-206.
27. Gentile S. Clinical utilization of atypical antipsychotics in pregnancy and lactation. Ann Pharmacother 2004;38:1265-71.
28. Collins KO, Comer JB. Maternal haloperidol therapy associated with dyskinesia in a newborn. Am J Health Syst Pharm 2003;60:2253-5.
29. Reis M, Kallen B. Maternal use of antipsychotics inearly pregnancy and delivery outcome. J Clin Psychopharmacol 2008;28:279-88.
30. Taylor D, Paton C, Kapur S. The Maudsley prescribing guidelines in psychiatry. 11th ed. Chichester, UK: Wiley-Blackwell, 2012.
31. McKean M. Psychiatric care during pregnancy and postpartum. Part 1: diagnosis and management of mood disorders. Psychopharm Rev 2013;48:17-24.
32. Jentink J, Loane MA, Dolk H, et al. Valproic acid monotherapyinpregnancy and major congenital malformations. N Engl J Med 2010;362:2185-93.
33. Cummings C, Stewart M, Stevenson M, Morrow J, Nelson J. Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Arch Dis Child 2011;96:643-7.
34. Cohen LS, Friedman JM, Jefferson JW, Johnson EM, Weiner ML. A reevaluation of risk of in utero exposure to lithium. JAMA 1994;271:146-50.
35. Miller LJ. Use of electroconvulsive therapy during pregnancy. Hosp Community Psychiatry 1994;45:444-50.
36. Yonkers KA, Wisner KL, Stowe Z, et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry 2004;161:608-20.
37. McElroy SL, Altshuler LL, Suppes T, et al. Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. Am J Psychiatry 2001;158:420-6.
38. Pettinati HM, O'Brien CP, Dundon WD. Current status of cooccurring mood and substance use disorders: a new therapeutic target. Am J Psychiatry 2013;170:23-30.
39. Salloum IM, Cornelius JR, Daley DC, Kirisci L, Himmelhoch JM, Thase ME. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebocontrolled study. Arch Gen Psychiatry 2005;62:37-45.
40. Brown ES, Gorman AR, Hynan LS. A randomized, placebocontrolled trial of citicoline add-on therapy in outpatients with bipolar disorder and cocaine dependence. J Clin Psychopharmacol 2007;27:498-502.
41. Chung AK, Chua SE. Effects on prolongation of Bazett's corrected QT interval of seven second-generation antipsychotics in the treatment of schizophrenia: a meta-analysis. J Psychopharmacol 2011;25:646-66.
42. Swann AC, Lafer B, Perugi G, et al. Bipolar mixed states: an international society for bipolar disorders task force report of symptom structure, course of illness, and diagnosis. Am J Psychiatry 2013;170:31-42.
43. Fountoulakis KN, Kontis D, Gonda X, Siamouli M, Yatham LN. Treatment of mixed bipolar states. Int J Neuropsychopharmacol 2012;15:1015-26.
44. McIntyre RS, Yoon J. Efficacy of antimanic treatments in mixed states. Bipolar Disord 2012;14 suppl 2:22-36.
45. Houston JP, Tohen M, Degenhardt EK, Jamal HH, Liu LL, Ketter TA. Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study. J Clin Psychiatry 2009;70:1540-7.
46. Suppes T, Ketter TA, Gwizdowski IS, et al. First controlled treatment trial of bipolar II hypomania with mixed symptoms: quetiapine versus placebo. J Affect Disord 2013;150:37-43.
47. Dunner DL. Atypical antipsychotics: efficacy across bipolar disorder subpopulations. J Clin Psychiatry 2005;66 suppl 3:20-7.
48. Kruger S, Trevor Young L, Braunig P. Pharmacotherapy of bipolar mixed states. Bipolar Disord 2005;7:205-15.
49. Cipriani A, Barbui C, Salanti G, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multipletreatments meta-analysis. Lancet 2011;378:1306-15.
50. Janicak PG, Rado JT. Quetiapine for the treatment of acute bipolar mania, mixed episodes and maintenance therapy. Expert Opin Pharmacother 2012;13:1645-52.
51. Weisler RH, Nolen WA, Neijber A, Hellqvist A, Paulsson B. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). J Clin Psychiatry 2011;72:1452-64.
52. Cutler AJ, Datto C, Nordenhem A, Minkwitz M, Acevedo L, Darko D. Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, doubleblind, 3-week trial. Clin Ther 2011;33:1643-58.
53. Vieta E, Nuamah IF, Lim P, et al. A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder. Bipolar Disord 2010;12:230-43.
54. Khazaal Y, Tapparel S, Chatton A, Rothen S, Preisig M, Zullino D. Quetiapine dosage in bipolar disorder episodes and mixed states. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:727-30.
55. Baker RW, Tohen M, Fawcett J, et al. Acute dysphoric mania: treatment response to olanzapine versus placebo. J Clin Psychopharmacol 2003;23:132-7.
56. Gonzalez-Pinto A, Lalaguna B, Mosquera F, et al. Use of olanzapine in dysphoric mania. J Affect Disord 2001;66:247-53.
57. Tohen M, McDonnell DP, Case M, et al. Randomised, doubleblind, placebo-controlled study of olanzapine in patients with bipolar I depression. Br J Psychiatry 2012;201:376-82.
58. McEvoy JP, Lieberman JA, Perkins DO, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007;164:1050-60.
59. Hahn MK, Wolever TM, Arenovich T, et al. Acute effects of single-dose olanzapine on metabolic, endocrine, and inflammatory markers in healthy controls. J Clin Psychopharmacol 2013;33:740-6.
60. Suppes T, Dennehy EB, Hirschfeld RM, etal. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry 2005;66:870-86.
61. Grunze H, Vieta E, Goodwin GM, etal. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry 2009;10:85-116.
62. Stahl S, Lombardo I, Loebel A, Mandel FS. Efficacy of ziprasidone in dysphoric mania: pooled analysis of two double-blind studies. J Affect Disord 2010;122:39-45.
63. Lombardo I, Sachs G, Kolluri S, Kremer C, Yang R. Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome? J Clin Psychopharmacol 2012;32:470-8.
64. Suppes T, Eudicone J, McQuade R, Pikalov A 3rd, Carlson B. Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder. J Affect Disord 2008;107:145-54.
65. Thase ME, Jonas A, Khan A, et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebocontrolled studies. J Clin Psychopharmacol 2008;28:13-20.
66. Zarate CA Jr, Rothschild A, Fletcher KE, Madrid A, Zapatel J. Clinical predictors of acute response with quetiapine in psychotic mood disorders. J Clin Psychiatry 2000;61:185-9.
67. Bowden CL, Swann AC, Calabrese JR, et al. A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania. J Clin Psychiatry 2006;67:1501-10.
68. Chengappa KN, Baker RW, Shao L, et al. Rates of response, euthymia and remission in two placebo-controlled olanzapine trials for bipolar mania. Bipolar Disord 2003;5:1-5.
69. Keck PE Jr, Marcus R, Tourkodimitris S, et al. A placebocontrolled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003;160:1651-8.
70. Marder SR, Sorsaburu S, Dunayevich E, et al. Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation. J Clin Psychiatry 2010;71:433-41.
71. Keck PE Jr, Mendlwicz J, Calabrese JR, et al. A review of randomized, controlled clinical trials in acute mania. J Affect Disord 2000;59 suppl 1:S31-S7.
72. Busch FN, Miller FT, Weiden PJ. A comparison of two adjunctive treatment strategies in acute mania. J Clin Psychiatry 1989;50:453-5.
73. Muller-Oerlinghausen B. Arguments for the specificity of the antisuicidal effect of lithium. Eur Arch Psychiatry Clin Neurosci 2001;251 suppl 2:II72-5.
74. Bauer MS, Mitchner L. What is a "mood stabilizer"? An evidencebased response. Am J Psychiatry 2004;161:3-18.
75. Ghaemi SN. From BALANCE to DSM-5: taking lithium seriously. Bipolar Disord 2010;12:673-7.
76. Goodwin FK, Whitham EA, Ghaemi SN. Maintenance treatment study designs in bipolar disorder: do they demonstrate that atypical neuroleptics (antipsychotics) are mood stabilizers? CNS Drugs 2011;25:819-27.
77. Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 2003;290:1467-73.
78. Baldessarini RJ, Tondo L, Davis P, Pompili M, Goodwin FK, Hennen J. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord 2006;8:625-39.
79. Cipriani A, Pretty H, Hawton K, Geddes JR. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic reviewof randomized trials. Am J Psychiatry 2005;162:1805-19.
80. Ahrens B, Muller-Oerlinghausen B. Does lithium exert an independent antisuicidal effect? Pharmacopsychiatry 2001;34:132-6.
81. Marangell LB, Dennehy EB, Wisniewski SR, et al. Case-control analyses of the impact of pharmacotherapy on prospectively observed suicide attempts and completed suicides in bipolar disorder: findings from STEP-BD. J Clin Psychiatry 2008;69:916-22.
82. Rybakowski JK, Suwalska A. Excellent lithium responders have normal cognitive functions and plasma BDNF levels. Int J Neuropsychopharmacol 2010;13:617-22.
83. Lyoo IK, Dager SR, Kim JE, et al. Lithium-induced gray matter volume increase as a neural correlate of treatment response in bipolar disorder: a longitudinal brain imaging study. Neuropsychopharmacology 2010;35:1743-50.
84. Moore GJ, Cortese BM, Glitz DA, et al. A longitudinal study of the effects of lithium treatment on prefrontal and subgenual prefrontal gray matter volume in treatment-responsive bipolar disorder patients. J Clin Psychiatry 2009;70:699-705.
85. Hajek T, Bauer M, Pfennig A, et al. Large positive effect of lithiumonprefrontal cortex N-acetylaspartate inpatients with bipolar disorder: 2-centre study. J Psychiatry Neurosci 2012;37:185-92.
86. Hajek T, Cullis J, Novak T, et al. Hippocampal volumes in bipolar disorders: opposing effects of illness burden and lithium treatment. Bipolar Disord 2012;14:261-70.
87. Hajek T, Kopecek M, Hoschl C, Alda M. Smaller hippocampal volumes in patients with bipolar disorder are masked by exposure to lithium: a meta-analysis. J Psychiatry Neurosci 2012;37:333-43.
88. Konopaske GT, Dorph-Petersen KA, Pierri JN, Wu Q, Sampson AR, Lewis DA. Effect of chronic exposure to antipsychotic medication on cell numbers in the parietal cortex of macaque monkeys. Neuropsychopharmacology 2007;32:1216-23.
89. Konopaske GT, Dorph-Petersen KA, Sweet RA, et al. Effect of chronic antipsychotic exposure on astrocyte and oligodendrocyte numbers in macaque monkeys. Biol Psychiatry 2008;63:759-65.
90. Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry 2011;68:128-37.
91. Mora E, Portella MJ, Forcada I, Vieta E, Mur M. Persistence of cognitive impairment and its negative impact on psychosocial functioning in lithium-treated, euthymic bipolar patients: a 6-year follow-up study. Psychol Med 2013;43:1187-96.
92. Baldessarini RJ, Leahy L, Arcona S, Gause D, Zhang W, Hennen J. Patterns of psychotropic drug prescription for U. S. patients with diagnoses of bipolar disorders. Psychiatr Serv 2007;58:85-91.
93. Kessing LV, Hellmund G, Geddes JR, Goodwin GM, Andersen PK. Valproate v. lithium in the treatment of bipolar disorder in clinical practice: observational nationwide register-based cohort study. Br J Psychiatry 2011;199:57-63.
94. Swann AC, Bowden CL, Calabrese JR, Dilsaver SC, Morris DD. Pattern of response to divalproex, lithium, or placebo in four naturalistic subtypes of mania. Neuropsychopharmacology 2002;26:530-6.
95. Lenox RH, Gould TD, Manji HK. Endophenotypes in bipolar disorder. Am J Med Genet 2002;114:391-406.
96. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA 1994;271:918-24.
97. Tondo L, Hennen J, Baldessarini RJ. Rapid-cycling bipolar disorder: effectsof long-term treatments. Acta Psychiatr Scand 2003;108:4-14.
98. Baldessarini RJ, Tondo L, Floris G, Hennen J. Effects of rapid cyclingonresponse tolithium maintenance treatmentin 360 bipolar I and II disorder patients. J Affect Disord 2000;61:13-22.
99. Calabrese JR, Rapport DJ, Youngstrom EA, Jackson K, Bilali S, Findling RL. New data on the use of lithium, divalproate, and lamotrigine in rapid cycling bipolar disorder. Eur Psychiatry 2005;20:92-5.
100. Hirschfeld RM, Allen MH, McEvoy JP, Keck PE Jr, Russell JM. Safety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients. J Clin Psychiatry 1999;60:815-8.
101. Kowatch RA, Suppes T, Carmody TJ, et al. Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2000;39:713-20.
102. Suppes T, Baldessarini RJ, Faedda GL, Tondo L, Tohen M. Discontinuation ofmaintenance treatment inbipolar disorder: risks and implications. Harv Rev Psychiatry 1993;1:131-44.
103. Goodwin GM. Recurrence of mania after lithium withdrawal. Implications for the use of lithium in the treatment of bipolar affective disorder. Br J Psychiatry 1994;164:149-52.
104. Cavanagh J, Smyth R, Goodwin GM. Relapse into mania or depression following lithium discontinuation: a 7-year follow-up. Acta Psychiatr Scand 2004;109:91-5.
105. Severus WE, Kleindienst N, Seemuller F, Frangou S, Moller HJ, Greil W. What is the optimal serum lithium level in the long-term treatment of bipolar disorder- A review? Bipolar Disord 2008;10:231-7.
106. Tamayo JM, Zarate CA Jr, Vieta E, Vazquez G, Tohen M. Level of response and safety of pharmacological monotherapy in the treatment of acute bipolar I disorder phases: a systematic review and meta-analysis. Int J Neuropsychopharmacol 2010;13:813-32.
107. Wagner KD, Ridden L, Kowatch RA, et al. A double-blind randomized, placebo-controlled trial of divalproex extendedrelease in the treatment of bipolar disorder in children and adolescents. J Am Acad Child Adolesc Psychiatry 2009;48:519-32.
108. Hirschfeld RM, Bowden CL, Vigna NV, Wozniak P, Collins M. A randomized, placebo-controlled, multicenter study of divalproex sodium extended-release in the acute treatment of mania. J Clin Psychiatry 2010;71:426-32.
109. Geddes JR, Goodwin GM, Rendell J, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 2010;375:385-95.
110. Nolen WA, Weisler RH. The association of the effect of lithium in the maintenance treatment of bipolar disorder with lithium plasma levels: a post hoc analysis of a double-blind study comparing switching to lithium or placebo in patients who responded to quetiapine (Trial 144). Bipolar Disord 2013;15:100-9.
111. Yatham LN, Paulsson B, Mullen J, Vagero AM. Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. J Clin Psychopharmacol 2004;24:599-606.
112. McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR. Lithium toxicity profile: a systematic review and meta-analysis. Lancet 2012;379:721-8.
113. Malhi GS, Berk M. Is the safety of lithium no longer in the balance? Lancet 2012;379:690-2.
114. Bowden CL, Grunze H, Mullen J, et al. A randomized, doubleblind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 2005;66:111-21.
115. Patel JK, Buckley PF, Woolson S, et al. Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study. Schizophr Res 2009;111:9-16.
116. Bendz H, Schon F, Attman PO, Aurell M. Renal failure occurs in chronic lithium treatment but is uncommon. Kidney Int 2010;77:219-24.
117. Yildiz A, Vieta E, Leucht S, Baldessarini RJ. Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropsychopharmacology 2011;36:375-89.
118. Correll CU, Sheridan EM, DelBello MP. Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. Bipolar Disord 2010;12:116-41.
119. Goikolea JM, Colom F, Capapey J, et al. Faster onset of antimanic action with haloperidol compared to second-generation antipsychotics. A meta-analysis of randomized clinical trials in acute mania. Eur Neuropsychopharmacol 2013;23:305-16.
120. Tohen M, Zarate CA Jr. Antipsychotic agents and bipolar disorder. J Clin Psychiatry 1998;59 suppl 1:38-48; discussion 9.
121. Zarate CA Jr, Tohen M. Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients. Am J Psychiatry 2004;161:169-71.
122. Yatham LN, Maj M. Bipolar disorder: clinical and neurobiological foundations. Chichester, UK: Wiley, 2010.
123. Gopal S, Steffens DC, Kramer ML, Olsen MK. Symptomatic remission in patients with bipolar mania: results from a doubleblind, placebo-controlled trial of risperidone monotherapy. J Clin Psychiatry 2005;66:1016-20.
124. Rendell JM, Gijsman HJ, Bauer MS, Goodwin GM, Geddes GR. Risperidone alone or in combination for acute mania. Cochrane Database Syst Rev 2006; (1): CD004043.
125. Shafti SS. Olanzapine vs. lithium in management of acute mania. J Affect Disord 2010;122:273-6.
126. Tariot PN, Schneider LS, Cummings J, et al. Chronic divalproex sodium failed to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry 2011;68:853-61.
127. Fleisher AS, Truran D, Mai JT, et al. Chronic divalproex sodium use and brain atrophy in Alzheimer disease. Neurology 2011;77:1263-71.
128. Pope HG Jr, McElroy SL, Keck PE Jr, Hudson JI. Valproate in the treatment of acute mania. A placebo-controlled study. Arch Gen Psychiatry 1991;48:62-8.
129. Müller J, Luderer HJ. [DEWIPA- A standardized questionnaire for assessing knowledge about symptoms, etiology and psychopharmacologic treatment in patients with depressive episodes]. Psychiatr Prax 1999;26:167-70.
130. Reinares M, Rosa AR, Franco C, et al. A systematic review on the role of anticonvulsants in the treatment of acute bipolar depression. Int J Neuropsychopharmacol 2013;16:485-96.
131. Akdeniz F, Taneli F, Noyan A, Yuncu Z, Vahip S. Valproateassociated reproductive and metabolic abnormalities: are epileptic women at greater risk than bipolar women? Prog Neuropsychopharmacol Biol Psychiatry 2003;27:115-21.
132. Liang CS, Yang FW, Lo SM. Rapid development of severe hypertriglyceridemia and hypercholesterolemia during augmentation of quetiapine with valproic acid. J Clin Psychopharmacol 2011;31:242-3.
133. Behzadi AH, Omrani Z, Chalian M, Asadi S, Ghadiri M. Folic acid efficacy as an alternative drug added to sodium valproate in the treatment of acute phase of mania in bipolar disorder: a double-blind randomized controlled trial. Acta Psychiatr Scand 2009;120:441-5.
134. Ketter TA, Kalali AH, Weisler RH. A 6-month, multicenter, open-label evaluation of beaded, extended-release carbamazepine capsule monotherapy in bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry 2004;65:668-73.
135. Versiani M, Cheniaux E, Landeira-Fernandez J. Efficacy and safety of electroconvulsive therapy in the treatment of bipolar disorder: a systematic review. J ECT 2011;27:153-64.
136. Small JG, Klapper MH, Kellams JJ, et al. Electroconvulsive treatment compared with lithium in the management of manic states. Arch Gen Psychiatry 1988;45:727-32.
137. Thomas J, Reddy B. The treatment of mania. A retrospective evaluation of the effects of ECT, chlorpromazine, and lithium. J Affect Disord 1982;4:85-92.
138. McCabe MS, Norris B. ECT versus chlorpromazine in mania. Biol Psychiatry 1977;12:245-54.
139. Geoffroy PA, Etain B, Henry C, Bellivier F. Combination therapy for manic phases: a critical review of a common practice. CNS Neurosci Ther 2012;18:957-64.
140. Gallego JA, Nielsen J, De Hert M, Kane JM, Correll CU. Safety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf 2012;11:527-42.
141. Ceron-Litvoc D, Soares BG, Geddes J, Litvoc J, de Lima MS. Comparison of carbamazepine and lithium in treatment of bipolar disorder: a systematic review of randomized controlled trials. Hum Psychopharmacol 2009;24:19-28.
142. Denicoff KD, Smith-Jackson EE, Disney ER, Ali SO, Leverich GS, Post RM. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997;58:470-8.
143. Baethge C, Baldessarini RJ, Mathiske-Schmidt K, et al. Longterm combination therapy versus monotherapy with lithium and carbamazepine in 46 bipolar I patients. J Clin Psychiatry 2005;66:174-82.
144. Klein E, Bental E, Lerer B, Belmaker RH. Carbamazepine and haloperidol v placebo and haloperidol in excited psychoses. A controlled study. Arch Gen Psychiatry 1984;41:165-70.
145. Small JG, Klapper MH, Marhenke JD, Milstein V, Woodham GC, Kellams JJ. Lithium combined with carbamazepine or haloperidol in the treatment of mania. Psychopharmacol Bull 1995;31:265-72.
146. Perlis RH, Welge JA, Vornik LA, Hirschfeld RM, Keck PE Jr. Atypical antipsychotics in the treatment of mania: a metaanalysis of randomized, placebo-controlled trials. J Clin Psychiatry 2006;67:509-16.
147. Fountoulakis KN, Vieta E. Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review. Ann Gen Psychiatry 2009;8:16.
148. Vieta E, T'joen C, McQuade RD, et al. Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study. Am J Psychiatry 2008;165:1316-25.
149. Tsai AC, Rosenlicht NZ, Jureidini JN, Parry PI, Spielmans GI, Healy D. Aripiprazole in the maintenance treatment of bipolar disorder: a critical review of the evidence and its dissemination into the scientific literature. PLoS Med 2011;8:e1000434.
150. Keck PE Jr, Versiani M, Potkin S, West SA, Giller E, Ice K. Ziprasidone in the treatment of acute bipolar mania: a threeweek, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003;160:741-8.
151. Potkin SG, Keck PE Jr, Segal S, Ice K, English P. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol 2005;25:301-10.
152. Vieta E, Ramey T, Keller D, English PA, Loebel AD, Miceli J. Ziprasidone in the treatment of acute mania: a 12-week, placebocontrolled, haloperidol-referenced study. J Psychopharmacol 2010;24:547-58.
153. Sachs GS, Vanderburg DG, Edman S, et al. Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 2: influence of protocol-specific eligibility criteria on signal detection. J Clin Psychiatry 2012;73:1420-5.
154. Sachs GS, Vanderburg DG, Edman S, et al. Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 1: results of a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2012;73:1412-9.
155. Miller S, Ittasakul P, Wang PW, et al. Enhanced ziprasidone combination therapy effectiveness in obese compared to nonobese patients with bipolar disorder. J Clin Psychopharmacol 2012;32:814-9.
156. Patkar A, Gilmer W, Pae CU, et al. A 6 week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state. PLoS One 2012;7:e34757.
157. Szegedi A, Calabrese JR, Stet L, Mackle M, Zhao J, Panagides J. Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension. J Clin Psychopharmacol 2012;32:46-55.
158. McIntyre RS. Asenapine: a review of acute and extension phase data in bipolar disorder. CNS Neurosci Ther 2011;17:645-8.
159. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study. J Affect Disord 2010;126:358-65.
160. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebocontrolled trial. J Affect Disord 2010;122:27-38.
161. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord 2009;11:673-86.
162. McElroy SL, Dessain EC, Pope HG Jr, et al. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J Clin Psychiatry 1991;52:411-4.
163. Calabrese JR, Kimmel SE, Woyshville MJ, et al. Clozapine for treatment-refractory mania. Am J Psychiatry 1996;153:759-64.
164. Barbini B, Scherillo P, Benedetti F, Crespi G, Colombo C, Smeraldi E. Response to clozapine in acute mania is more rapid than that of chlorpromazine. Int Clin Psychopharmacol 1997;12:109-12.
165. Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush AJ. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry 1999;156:1164-9.
166. Melvin CL, Carey TS, Goodman F, Oldham JM, Williams JW Jr, Ranney LM. Effectiveness of antiepileptic drugs for the treatment of bipolar disorder: findings from a systematic review. J Psychiatr Pract 2008;14 suppl 1:9-14.
167. Grunze H, Langosch J, Born C, Schaub G, Walden J. Levetiracetam in the treatment of acute mania: an open add-on study with an on-off-on design. J Clin Psychiatry 2003;64:781-4.
168. Kruger S, Sarkar R, Pietsch R, Hasenclever D, Braunig P. Levetiracetam as monotherapy or add-on to valproate in the treatment of acute mania- A randomized open-label study. Psychopharmacology (Berl) 2008;198:297-9.
169. Wagner KD, Kowatch RA, Emslie GJ, et al. A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. Am J Psychiatry 2006;163:1179-86.
170. Vieta E, Cruz N, Garcia-Campayo J, et al. A double-blind, randomized, placebo-controlled prophylaxis trial of oxcarbazepine as adjunctive treatment to lithium in the long-term treatment of bipolar I and II disorder. Int J Neuropsychopharmacol 2008;11:445-52.
171. Vasudev A, Macritchie K, Vasudev K, Watson S, Geddes J, Young AH. Oxcarbazepine for acute affective episodes in bipolar disorder. Cochrane Database Syst Rev 2011; (12): CD004857.
172. Kushner SF, Khan A, Lane R, Olson WH. Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials. Bipolar Disord 2006;8:15-27.
173. Vigo DV, Baldessarini RJ. Anticonvulsants in the treatment of major depressive disorder: an overview. Harv Rev Psychiatry 2009;17:231-41.
174. Arnone D. Review of the use of topiramate for treatment of psychiatric disorders. Ann Gen Psychiatry 2005;4:5.
175. Thomas P, Vieta E. Amisulpride plus valproate vs haloperidol plus valproate in the treatment of acute mania of bipolar I patients: a multicenter, open-label, randomized, comparative trial. Neuropsychiatr Dis Treat 2008;4:675-86.
176. Berwaerts J, Lane R, Nuamah F, et al. Paliperidone XR as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study. J Affect Disord 2011;129:252-60.
177. Machado-Vieira R, Soares JC, Lara DR, et al. A doubleblind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania. J Clin Psychiatry 2008;69:1237-45.
178. Fan A, Berg A, Bresee C, Glassman LH, Rapaport MH. Allopurinol augmentation in the outpatient treatment of bipolar mania: a pilot study. Bipolar Disord 2012;14:206-10.
179. Akhondzadeh S, Milajerdi MR, Amini H, Tehrani-Doost M. Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double-blind, randomized, placebo-controlled trial. Bipolar Disord 2006;8:485-9.
180. Stolk P, Souverein PC, Wilting I, et al. Is aspirin useful in patients on lithium? A pharmacoepidemiological study related to bipolar disorder. Prostaglandins Leukot Essent Fatty Acids 2010;82:9-14.
181. Montgomery P, Richardson AJ. Omega-3 fatty acids for bipolar disorder. Cochrane Database Syst Rev 2008; (2): CD005169.
182. Murphy BL, Stoll AL, Harris PQ, et al. Omega-3 fatty acid treatment, with or without cytidine, fails to show therapeutic properties in bipolar disorder: a double-blind, randomized add-on clinical trial. J Clin Psychopharmacol 2012;32:699-703.
183. Yildiz A, Guleryuz S, Ankerst DP, Ongur D, Renshaw PF. Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen. Arch Gen Psychiatry 2008;65:255-63.
184. Kulkarni J, Garland KA, Scaffidi A, et al. A pilot study of hormone modulation as a new treatment for mania in women with bipolar affective disorder. Psychoneuroendocrinology 2006;31:543-7.
185. Zarate CA Jr, Singh JB, Carlson PJ, et al. Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord 2007;9:561-70.
186. Amrollahi Z, Rezaei F, Salehi B, et al. Double-blind, randomized, placebo-controlled 6-week study on the efficacy and safety of the tamoxifen adjunctive to lithium in acute bipolar mania. J Affect Disord 2011;129:327-31.
187. Gilmer WS, Zarnicki JN. Review of transcranial magnetic stimulation for bipolar disorder. Psychopharm Rev 2012;47:25-30.
188. Yatham LN 1, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord 2013;15:1-44.
189. Goodwin GM; Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition-recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009;23:346-88.
190. Suppes T, Dennehy EB, Hirschfeld RM, et al.; Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry 2005;66:870-86.